Compare TJX Companies Inc (TJX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Zoetis Inc — how do they compare? TJX Companies Inc trades at $126.32 (market cap $141.81B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: TJX Companies Inc is far larger — about 4.7× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| TJX | ZTS | |
|---|---|---|
Market Cap | $141.81B | $30.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $150.61 |
52-Week Low | $126.10 | $71.91 |
Enterprise Value | $150.12B | $37.96B |
Dividend Yield | 1.49% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX Companies (TJX) trades at $128.91, down 2.4% over 24 hours, with technical indicators showing bearish momentum but oversold RSI signals. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.22 exceeding expectations. Revenue grew to $56.36 billion in 2025, and net income margin improved to 9.73%. Analysts maintain a bullish consensus with 84.6% buy ratings and a $169 price target, citing expansion plans to 7,500 stores.
The outlook for TJX is positive due to consistent earnings outperformance and robust store growth strategy, though near-term stock pressure reflects valuation concerns and competitive comparisons. Key risks include market volatility and execution challenges in scaling operations. Investors may find opportunity in the current dip given strong fundamentals and analyst support.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
